(Reuters) -Annovis Bio said on Monday its Alzheimer’s treatment showed significantly higher improvement in cognition in patients during a mid-stage trial.
The company’s drug buntanetap works by decreasing the production of amyloid beta protein, believed to be a hallmark of Alzheimer’s, from the brain.
Annovis plans to conduct a late-stage trial based on results of this trial.
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
